-

ElevateBio to Present at the 40th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--ElevateBio, LLC, a technology-driven company focused on powering transformative cell and gene therapies, today announced it will present at the J.P. Morgan 40th Annual Healthcare Conference to be held virtually January 10-13, 2022.

David Hallal, Chairman and Chief Executive Officer, will present in a virtual format on January 10, 2022 at 11:00 a.m. ET, which will be accessible to registered conference attendees.

About ElevateBio:

ElevateBio is a technology-driven company built to power the development of transformative cell and gene therapies today and for many decades to come. ElevateBio has assembled industry-leading talent, built world-class facilities, and integrated diverse technology platforms necessary to drive innovation and commercialization of cell, gene, and regenerative therapies. ElevateBio has built a technology stack, including gene editing, induced pluripotent stem cells, and protein, viral, and cellular engineering, that can be leveraged across the entire portfolio and by strategic partners. In addition, BaseCamp is a purpose-built facility offering process innovation, process sciences, and current Good Manufacturing Practice (cGMP) manufacturing capabilities. Through BaseCamp and its enabling technologies, ElevateBio is focused on growing its collaborations with industry partners while also developing its own portfolio of cellular and genetic medicines. ElevateBio's team of scientists, drug developers, and company builders are redefining what it means to be a technology company in the world of drug development, blurring the line between technology and healthcare.

ElevateBio is located in Waltham, MA. Visit us at www.elevate.bio, or follow ElevateBio on LinkedIn, Twitter, or Instagram.

Contacts

Investor Contact:
Catherine Hu
chu@elevate.bio
646-535-8276

Media Contact:
Courtney Heath
ScientPR
Courtney@scientpr.com
617-872-2462

ElevateBio, LLC


Release Summary
ElevateBio to Present at the 40th Annual J.P. Morgan Healthcare Conference
Release Versions

Contacts

Investor Contact:
Catherine Hu
chu@elevate.bio
646-535-8276

Media Contact:
Courtney Heath
ScientPR
Courtney@scientpr.com
617-872-2462

Social Media Profiles
More News From ElevateBio, LLC

ElevateBio Announces Presentations at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

WALTHAM, Mass.--(BUSINESS WIRE)--ElevateBio, LLC (ElevateBio), a technology-driven company focused on powering the creation of life-transforming genetic medicines, today announced four poster presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting taking place May 7-11, in Baltimore, MD. The poster presentations will detail ElevateBio’s expertise in optimizing the development and manufacturing of genetic medicines, including scalable screening and man...

ElevateBio to Highlight Growth of its Genetic Medicine Business Driven By Gene Editing and Manufacturing Partnerships at the 42nd Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass.--(BUSINESS WIRE)--ElevateBio, LLC (ElevateBio), a technology-driven company focused on powering the creation of life-transforming genetic medicines, today announced advancements across its ecosystem of technology platforms and manufacturing capabilities that enable the biopharmaceutical industry to discover, develop, manufacture, and commercialize a broad range of advanced therapeutics. ElevateBio is accelerating the genetic medicine space through 20+ partnerships for a range of...

ElevateBio Announces $401 Million Series D Financing to Further Accelerate Growth

WALTHAM, Mass.--(BUSINESS WIRE)--ElevateBio, LLC (ElevateBio), a technology-driven company focused on powering the creation of life-transforming cell and gene therapies, today announced the closing of its $401 million Series D financing led by the AyurMaya Capital Management Fund, managed by Matrix Capital Management, and joined by a leading group of new and existing investors. ElevateBio’s syndicate now includes new investors Woodline, Lee Family Office (Asia), and R&D partner Novo Nordisk...
Back to Newsroom